Trubion Pharmaceuticals, a biopharmaceutical company developing drugs to treat rheumatoid arthritis and systemic lupus erythematosus, filed an S-1 registration statement with the SEC on Friday. The Seattle, WA based company has selected Morgan Stanley to lead manage its IPO. Terms and timing for the offering have yet to be announced.
